| 名稱 | Anacetrapib |
| 描述 | Anacetrapib (MK-0859) (MK0859) is an effective, specific, reversible rhCETP and mutant CETP(C13S) inhibitor (IC50: 7.9 nM and 11.8 nM). Anacetrapib reduces the transfer of cholesteryl ester from HDL to LDL and/or VLDL thereby, producing an increase in serum HDL-cholesterol levels and a decrease in serum LDL-cholesterol levels. |
| 細胞實驗 | Anacetrapib (ANA) is dissolved in DMSO and diluted with appropriate media[2]. Cells are seeded in a 96 well plate overnight prior to the treatment by different concentrations of CETP inhibitors (e.g., Anacetrapib) for 24 h. Cell viability is measured using the CellTiter-Glo Luminescent Cell Viability Assay kit. Four wells are evaluated under each experimental condition[2]. |
| 激酶實驗 | The inhibitory potency (IC50) of Dalcetrapib, Torcetrapib, and Anacetrapib to decrease CE transfer from HDL to LDL by rhCETP and C13S CETP is measured using a scintillation proximity assay kit. Briefly, [3H]CE-labeled HDL donor particles are incubated in the presence of purified CETP proteins (final concentration 0.5 μg/mL) and biotinylated LDL acceptor particles for 3 h at 37°C. Subsequently, streptavidin-coupled polyvinyltoluene beads containing liquid scintillation cocktail binding selectively to biotinylated LDL are added, and the amount of [3H]CE molecules transferred to LDL is measured by β counting[1]. |
| 體外活性 | Anacetrapib對巨噬細胞膽固醇逆向轉運有促進作用,可增加30%的排泄物膽固醇含量.處理異常倉鼠模型,持續(xù)處理2周,與對照組相比,Anacetrapib （60 mg/kg/day）使CETP活性下降94%,HDL-膽固醇上升47%,不影響非HDL膽固醇濃度.與對照組相比,Anacetrapib處理的倉鼠HDL顯示ABCG1和SR-B1調節(jié)的流出物增多. [14C]Anacetrapib（10 mg/kg,p.o.）給藥48 h后,鼠和猴分別恢復～80和90%放射性,但排泄物中放射性幾乎無變化. |
| 體內活性 | Anacetrapib和抑制素聯(lián)用時,既可提高HDL-膽固醇水平,也可降低LDL-膽固醇水平。Anacetrapib劑量依賴性地抑制CE從HDL3轉變?yōu)镠DL2。Anacetrapib對[14C]-dalcetrapibthiol與人類重組CETP的結合數無影響。 |
| 存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| 溶解度 | H2O : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 250 mg/mL (392.15 mM), Sonication is recommended.
10% DMSO+90% Corn Oil : 2.5 mg/mL (3.92 mM), Sonication is recommended.
10% DMSO+40% PEG300+ 5% Tween 80 + 45% Saline : 10 mg/mL (15.69 mM), Suspension.
10% DMSO+90% Saline : < 10 mg/mL (15.69 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
Ethanol : 57 mg/mL (89.41 mM), Sonication is recommended.
|
| 關鍵字 | rhCETP | Mutant CETP (C13S) | MK0859 | MK 0859 | Inhibitor | inhibit | Cholesteryl ester transfer protein | CETP | Anacetrapib |
| 相關產品 | Dalcetrapib | 3-Pyridinemethanol | Obicetrapib | 20-HC-Me-Pyrrolidine | BMS-188494 | CETP-IN-4 | Torcetrapib | CP-532623 | Implitapide | Erabulenol A | Evacetrapib | CETP-IN-3 |
| 相關庫 | 抑制劑庫 | 脂代謝化合物庫 | 經典已知活性庫 | 已知活性化合物庫 | 代謝化合物庫 | 抗心血管疾病化合物庫 | NO PAINS 化合物庫 | 抗肥胖化合物庫 | 臨床期小分子藥物庫 | 藥物功能重定位化合物庫 | 抗代謝疾病化合物庫 | 表型篩選靶點鑒定庫 |